Elimination of ketoprofen from the stratum corneum after topical administration with ketoprofen formulations in human subjects

Masahiko Takeshi, Tamotsu Ebihara, Kotaro Maekawa, Kaori Yamamoto, Naruhito Higo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: To assess the drug concentrations and elimination rate of ketoprofen in the stratum corneum following topical administration of two different formulations in human subjects for reference in the risk management of photocontact dermatitis caused by topical ketoprofen. Methods: Ketoprofen tape and gel were used as test formulations. The stratum corneum at the application sites was removed by tape-stripping at scheduled times after removal of the formulations. The ketoprofen concentration in the stratum corneum was determined by liquid chromatography with tandem mass spectrometry. Results: The ketoprofen concentration in the stratum corneum decreased and the elimination half-life in the stratum corneum was comparable between tape and gel after removal of the test formulations. The ketoprofen concentration in the stratum corneum decreased more rapidly after the subjects took a shower. Ketoprofen was not detected in the stratum corneum adjacent to the tape application sites. Conclusions: Ketoprofen in the stratum corneum appears to reach the lower limit of quantitation (0.005 μg) 12-16 days after removal of tape or gel. This period is similar to that recommended for avoiding ultraviolet light after removal of topical ketoprofen formulations in the Summary of Product Characteristics for topical ketoprofen in the European Union.

Original languageEnglish
Pages (from-to)197-201
Number of pages5
JournalInternational Journal of Pharmaceutics
Volume465
Issue number1-2
DOIs
Publication statusPublished - 2014 Apr 25

Fingerprint

Ketoprofen
Topical Administration
Cornea
Gels
Photoallergic Dermatitis
Risk Management
European Union
Ultraviolet Rays
Tandem Mass Spectrometry
Liquid Chromatography
Half-Life

Keywords

  • Elimination half-life
  • Gel formulation
  • Ketoprofen
  • Photocontact dermatitis
  • Tape formulation

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Medicine(all)

Cite this

Elimination of ketoprofen from the stratum corneum after topical administration with ketoprofen formulations in human subjects. / Takeshi, Masahiko; Ebihara, Tamotsu; Maekawa, Kotaro; Yamamoto, Kaori; Higo, Naruhito.

In: International Journal of Pharmaceutics, Vol. 465, No. 1-2, 25.04.2014, p. 197-201.

Research output: Contribution to journalArticle

Takeshi, Masahiko ; Ebihara, Tamotsu ; Maekawa, Kotaro ; Yamamoto, Kaori ; Higo, Naruhito. / Elimination of ketoprofen from the stratum corneum after topical administration with ketoprofen formulations in human subjects. In: International Journal of Pharmaceutics. 2014 ; Vol. 465, No. 1-2. pp. 197-201.
@article{52dc7b91775a4c79bc1c0b952e598659,
title = "Elimination of ketoprofen from the stratum corneum after topical administration with ketoprofen formulations in human subjects",
abstract = "Purpose: To assess the drug concentrations and elimination rate of ketoprofen in the stratum corneum following topical administration of two different formulations in human subjects for reference in the risk management of photocontact dermatitis caused by topical ketoprofen. Methods: Ketoprofen tape and gel were used as test formulations. The stratum corneum at the application sites was removed by tape-stripping at scheduled times after removal of the formulations. The ketoprofen concentration in the stratum corneum was determined by liquid chromatography with tandem mass spectrometry. Results: The ketoprofen concentration in the stratum corneum decreased and the elimination half-life in the stratum corneum was comparable between tape and gel after removal of the test formulations. The ketoprofen concentration in the stratum corneum decreased more rapidly after the subjects took a shower. Ketoprofen was not detected in the stratum corneum adjacent to the tape application sites. Conclusions: Ketoprofen in the stratum corneum appears to reach the lower limit of quantitation (0.005 μg) 12-16 days after removal of tape or gel. This period is similar to that recommended for avoiding ultraviolet light after removal of topical ketoprofen formulations in the Summary of Product Characteristics for topical ketoprofen in the European Union.",
keywords = "Elimination half-life, Gel formulation, Ketoprofen, Photocontact dermatitis, Tape formulation",
author = "Masahiko Takeshi and Tamotsu Ebihara and Kotaro Maekawa and Kaori Yamamoto and Naruhito Higo",
year = "2014",
month = "4",
day = "25",
doi = "10.1016/j.ijpharm.2014.02.015",
language = "English",
volume = "465",
pages = "197--201",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Elimination of ketoprofen from the stratum corneum after topical administration with ketoprofen formulations in human subjects

AU - Takeshi, Masahiko

AU - Ebihara, Tamotsu

AU - Maekawa, Kotaro

AU - Yamamoto, Kaori

AU - Higo, Naruhito

PY - 2014/4/25

Y1 - 2014/4/25

N2 - Purpose: To assess the drug concentrations and elimination rate of ketoprofen in the stratum corneum following topical administration of two different formulations in human subjects for reference in the risk management of photocontact dermatitis caused by topical ketoprofen. Methods: Ketoprofen tape and gel were used as test formulations. The stratum corneum at the application sites was removed by tape-stripping at scheduled times after removal of the formulations. The ketoprofen concentration in the stratum corneum was determined by liquid chromatography with tandem mass spectrometry. Results: The ketoprofen concentration in the stratum corneum decreased and the elimination half-life in the stratum corneum was comparable between tape and gel after removal of the test formulations. The ketoprofen concentration in the stratum corneum decreased more rapidly after the subjects took a shower. Ketoprofen was not detected in the stratum corneum adjacent to the tape application sites. Conclusions: Ketoprofen in the stratum corneum appears to reach the lower limit of quantitation (0.005 μg) 12-16 days after removal of tape or gel. This period is similar to that recommended for avoiding ultraviolet light after removal of topical ketoprofen formulations in the Summary of Product Characteristics for topical ketoprofen in the European Union.

AB - Purpose: To assess the drug concentrations and elimination rate of ketoprofen in the stratum corneum following topical administration of two different formulations in human subjects for reference in the risk management of photocontact dermatitis caused by topical ketoprofen. Methods: Ketoprofen tape and gel were used as test formulations. The stratum corneum at the application sites was removed by tape-stripping at scheduled times after removal of the formulations. The ketoprofen concentration in the stratum corneum was determined by liquid chromatography with tandem mass spectrometry. Results: The ketoprofen concentration in the stratum corneum decreased and the elimination half-life in the stratum corneum was comparable between tape and gel after removal of the test formulations. The ketoprofen concentration in the stratum corneum decreased more rapidly after the subjects took a shower. Ketoprofen was not detected in the stratum corneum adjacent to the tape application sites. Conclusions: Ketoprofen in the stratum corneum appears to reach the lower limit of quantitation (0.005 μg) 12-16 days after removal of tape or gel. This period is similar to that recommended for avoiding ultraviolet light after removal of topical ketoprofen formulations in the Summary of Product Characteristics for topical ketoprofen in the European Union.

KW - Elimination half-life

KW - Gel formulation

KW - Ketoprofen

KW - Photocontact dermatitis

KW - Tape formulation

UR - http://www.scopus.com/inward/record.url?scp=84898599748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898599748&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2014.02.015

DO - 10.1016/j.ijpharm.2014.02.015

M3 - Article

C2 - 24530385

AN - SCOPUS:84898599748

VL - 465

SP - 197

EP - 201

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -